Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.
U.S. authorities said 24 defendants were charged in connection with one of the largest healthcare fraud schemes prosecuted by the federal government, involving telemedicine companies and resulting in more than $1.2 billion of losses.
